Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONCT POWR Grades
- ONCT scores best on the Sentiment dimension, with a Sentiment rank ahead of 64.65% of US stocks.
- ONCT's strongest trending metric is Momentum; it's been moving down over the last 51 weeks.
- ONCT ranks lowest in Momentum; there it ranks in the 4th percentile.
ONCT Stock Summary
- The ratio of debt to operating expenses for Oncternal Therapeutics Inc is higher than it is for about only 5.17% of US stocks.
- With a price/sales ratio of 52.84, Oncternal Therapeutics Inc has a higher such ratio than 95.27% of stocks in our set.
- Oncternal Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -54.67%, greater than the shareholder yield of just 5.22% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Oncternal Therapeutics Inc, a group of peers worth examining would be YMAB, FOLD, CLSD, ACET, and EXEL.
- ONCT's SEC filings can be seen here. And to visit Oncternal Therapeutics Inc's official web site, go to www.oncternal.com.
ONCT Valuation Summary
- ONCT's price/sales ratio is 58.7; this is 1444.74% higher than that of the median Healthcare stock.
- ONCT's EV/EBIT ratio has moved up 15.2 over the prior 214 months.
- ONCT's EV/EBIT ratio has moved up 15.2 over the prior 214 months.
Below are key valuation metrics over time for ONCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ONCT | 2021-08-31 | 58.7 | 2.2 | -10.8 | -5.8 |
| ONCT | 2021-08-30 | 56.5 | 2.1 | -10.4 | -5.4 |
| ONCT | 2021-08-27 | 57.1 | 2.1 | -10.6 | -5.5 |
| ONCT | 2021-08-26 | 54.9 | 2.0 | -10.1 | -5.1 |
| ONCT | 2021-08-25 | 53.5 | 2.0 | -9.9 | -4.9 |
| ONCT | 2021-08-24 | 54.8 | 2.0 | -10.1 | -5.1 |
ONCT Growth Metrics
- Its 5 year net income to common stockholders growth rate is now at -22.05%.
- Its 5 year price growth rate is now at -96.63%.
- Its 4 year net income to common stockholders growth rate is now at -157.74%.
The table below shows ONCT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 3.804 | -22.831 | -20.582 |
| 2021-03-31 | 3.544 | -19.444 | -18.435 |
| 2020-12-31 | 3.375 | -17.495 | -17.225 |
| 2020-12-31 | 3.375 | -17.495 | -17.225 |
| 2020-09-30 | 2.522 | -16.629 | -18.824 |
| 2020-06-30 | 2.481 | -15.131 | -19.321 |
ONCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ONCT has a Quality Grade of D, ranking ahead of 15.21% of graded US stocks.
- ONCT's asset turnover comes in at 0.042 -- ranking 334th of 681 Pharmaceutical Products stocks.
- CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with ONCT.
The table below shows ONCT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.042 | 1 | 6.705 |
| 2021-03-31 | 0.051 | 1 | 4.190 |
| 2020-12-31 | 0.075 | 1 | 3.387 |
| 2020-12-31 | 0.075 | 1 | 3.387 |
| 2020-09-30 | 0.123 | 1 | 3.414 |
| 2020-06-30 | 0.119 | 1 | 3.551 |
ONCT Price Target
For more insight on analysts targets of ONCT, see our ONCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.50 | Average Broker Recommendation | 1.38 (Strong Buy) |
ONCT Stock Price Chart Interactive Chart >
ONCT Price/Volume Stats
| Current price | $3.87 | 52-week high | $10.56 |
| Prev. close | $4.07 | 52-week low | $1.49 |
| Day low | $3.85 | Volume | 534,700 |
| Day high | $4.15 | Avg. volume | 1,173,337 |
| 50-day MA | $4.09 | Dividend yield | N/A |
| 200-day MA | $5.46 | Market Cap | 191.12M |
Oncternal Therapeutics, Inc. (ONCT) Company Bio
Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.
Latest ONCT News From Around the Web
Below are the latest news stories about Oncternal Therapeutics Inc that investors may wish to consider to help them evaluate ONCT as an investment opportunity.
Companies Like Oncternal Therapeutics (NASDAQ:ONCT) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsAndrogen Receptor (AR) inhibition is an important therapeutic approach for the treatment of Castration-Resistant Prostate Cancer (CRPC), but AR-escape mechanisms related to the expression of AR splice variants (AR-SV), such as AR-V7, represent a significant unmet need and are a key area of focus for novel therapies in developmentONCT-534 may become a promising next-generation treatment option for CRPC and for the clinically-important emerging class of AR-SV-expressing prostate cancers SAN DIEGO, |
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to Emily Samec, who joined the Company as Vice President, Operations and Project Management, and 3 new non-executive employees. The awards were made on October 1, 2021 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the |
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular TherapiesFLORHAM PARK, N.J. and SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced they have entered into a research collaboration to evaluate placental derived-cellular therapies targe |
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular TherapiesSAN DIEGO and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, and Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced they have entered into a research collaboration to evaluate placental derived-cellular therapies targe |
ONCT Price Returns
| 1-mo | -8.73% |
| 3-mo | -6.97% |
| 6-mo | -32.70% |
| 1-year | 129.67% |
| 3-year | -70.44% |
| 5-year | -93.92% |
| YTD | -21.02% |
| 2020 | 24.05% |
| 2019 | -27.66% |
| 2018 | -93.86% |
| 2017 | 140.72% |
| 2016 | -24.57% |
Loading social stream, please wait...